Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Okayama University Research: New Mouse Model for Studying Pancreatic Cancer
  • USA - English


News provided by

Okayama University

Feb 17, 2017, 07:00 ET

Share this article

Share toX

Share this article

Share toX

Sections from serial primary tumors showing the histopathological adenocarcinoma-like morphology. H&E staining.
Sections from serial primary tumors showing the histopathological adenocarcinoma-like morphology. H&E staining.

Okayama, Japan (PRWEB UK) 17 February 2017 -- Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 17 February 2017

(Okayama, 17 February 2017) Researchers at Okayama University report in the American Journal of Cancer Research a novel in vivo model for the study of pancreatic ductal adenocarcinoma (PDAC) tumors. The model relies on induced pluripotent stem cell conversion; the artificially generated cell lines exhibit the PDAC phenotype and are expected to help our understanding of pancreatic cancer.

Future research based on this mouse model is expected to lead to further valuable insights into the origin of pancreatic cancer that might ultimately lead to a cure.

Post this

Pancreatic ductal adenocarcinoma (PDAC) tumors, typical manifestations of pancreatic cancer, are known to be strongly resistant to radiation therapy and chemotherapy. For finding a cure for the disease, it is essential to develop representative mouse models of PDAC tumors. An international team of researchers including Masaharu Seno and colleagues from Okayama University have now devised a new method for generating PDAC tumors in vivo — providing a promising platform for investigating pancreatic cancer.

Among the different types of cells that are present in a PDAC tumor, cancer stem cells are the ones associated with tumor initiation. Using the technique of induced pluripotent stem cell (iPSC) conversion, the researchers generated in vitro pancreatic cancer stem cell lines (CSCcm) in the lab that have properties of cancer stem cells. The iPSC-converted cell lines led, after being transplanted into mice, to tumors with the PDAC phenotype, which can hence serve as models for the study of PDAC occurrence and progression.

The researchers point out that, importantly, their approach involves no genetic manipulation. Indeed, until now, mouse models used for studying pancreatic cancer were usually genetically engineered — a problem when trying to understand spontaneous tumor occurrence.

In order for the in vitro iPSC-converted cell lines to develop the features of cancer stem cells, they need to be introduced into a mouse or other organism, which is not ideal. “This reliance on in vivo systems is an unresolved matter that must eventually be overcome,” says Seno.

The researchers already used their novel model to address the issue regarding certain single-point mutations often seen in PDAC tumors. A preliminary analysis shows that these mutations are not observed for the CSCcm lines, and that there is therefore no correlation with tumor initiation. Future research based on this mouse model is expected to lead to further valuable insights into the origin of pancreatic cancer that might ultimately lead to a cure.

Background
Induced pluripotent stem cells (iPSCs) and regenerative medicine
Stem cells are cells that have the ability to differentiate — that is, become cells of a specialized type. An important attribute of a stem cell is its potency, indicating into what types of cells the stem cell can differentiate. So-called pluripotent stem cells (PSCs) can develop into organisms, because they can differentiate into cells of any of the three different germ layers characteristic of organisms.

An induced pluripotent stem cell (iPSC) is a PSC artificially generated from a non-PSC. The procedure for creating iPSCs was discovered in 2006 by Shinya Yamanaka. Nowadays, iPSC generation is a promising technique in the field of regenerative medicine: damaged or badly functioning human cells can be replaced by cells properly differentiated from iPSCs.

Seno and colleagues used a technique based on iPSC conversion where they converted iPSC lines into cancer stem cells that mimic pancreatic cancer stem cells.

Pancreatic ductal adenocarcinoma (PDAC) tumors
The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC). PDAC tumors consist of different types of cells: cancer stem cells (CSCs), differentiated cancer cells, tumor-associated pluripotent cells and immune cells. For induced pluripotent stem cells (iPSCs) to be converted into cell lines leading to valid mouse tumor models, they have to be sufficiently similar to the CSCs, as these are the ones believed to be linked to tumor initiation. The researchers were able to confirm that their iPSC-converted cell lines recapitulated the PDAC tumor phenotype — which signifies an important step towards new diagnostic approaches and a better understanding of PDAC tumor origin and progression.

Reference
Anna Sanchez Calle, Neha Nair, Aung KoKo Oo, Marta Prieto, Megumi Koga, Apriliana Cahya Khayrani, Maram Hussein, Laura Hurley, Arun Vaidyanath, Akimasa Seno, Yoshiaki Iwasaki, Malu Calle, Tomonari Kasai, Masaharu Seno. A new PDAC mouse model originated from iPSCs-converted pancreatic Cancer Stem Cells (CSCcm). American Journal of Cancer Research, 2016; 6(12): 2799–2815.
ISSN: 2156-6976
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5199755/

Further information
Okayama University
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: http://www.adm(at)adm(dot)okayama-u.ac(dot)jp

Website: http://www.okayama-u.ac.jp/index_e.html
Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/

About Okayama University (You Tube):
https://www.youtube.com/watch?v=iDL1coqPRYI

Okayama University Medical Research Updates (OU-MRU)
Volumes 1 to 33

Vol.1:Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testing
http://www.okayama-u.ac.jp/up_load_files/ebulletin-RUs/vol1/vol.1.pdf

Vol.33:Attacking tumors from the inside
http://www.okayama-u.ac.jp/eng/research_highlights/index_id44.html

H. Tokiwa, Okayama University, +81 9065213797, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.